Bicara Therapeutics Inc. (NASDAQ:BCAX) shares gained 3.32% in pre-market trading on Tuesday after the clinical-stage biopharmaceutical company reported continued enrollment progress in its pivotal FORTIFI-HN01 study and maintained its timeline for an interim analysis in 2027.
The company reported a second-quarter loss of $0.82 per share for the period ended June 30, 2026. Net loss widened to $55.4 million from $27.4 million in the same quarter last year as spending increased around the pivotal clinical programme.
FORTIFI-HN01 remains on track for key 2027 readout
Bicara said it remains on schedule to achieve substantial enrollment in FORTIFI-HN01 by the end of 2026.
That pace is expected to support topline results from an interim analysis in mid-2027, making enrollment progress an important near-term measure for investors tracking the development of ficerafusp alfa in head and neck cancer.
“This transition marks a natural evolution for Bicara as we maintain strong enrollment momentum that enables a clear line of sight to a topline interim analysis which we believe will lead to an accelerated approval and subsequent launch of ficerafusp alfa in head and neck cancer,” said Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics.
The company has also initiated FORTIFI-FLEX, a study evaluating an alternative dosing regimen of ficerafusp alfa in combination with pembrolizumab.
Clinical investment pushes quarterly expenses higher
Bicara’s expanding clinical programme contributed to a significant increase in operating expenses during the quarter.
Research and development expenses rose to $45.8 million from $24.8 million a year earlier, primarily due to spending associated with the ongoing FORTIFI-HN01 pivotal trial.
General and administrative expenses increased to $14.2 million from $7.2 million. The company attributed the rise to additional personnel expenses and professional fees as it prepares for potential commercialisation.
The higher spending helped drive the quarterly net loss to $55.4 million, highlighting the cost of advancing ficerafusp alfa through late-stage development.
Bicara cash runway extends into 2029
Despite the higher cash requirements of its clinical programmes, Bicara reported a substantial liquidity position.
Cash, cash equivalents and marketable securities stood at $497.3 million as of June 30, up from $414.8 million at the end of 2025.
Management expects its existing resources to fund operations into the first half of 2029, providing financial runway through the planned mid-2027 FORTIFI-HN01 interim analysis.
CEO transition planned for January 2027
Bicara also announced a leadership change ahead of the expected clinical milestone.
Ryan Cohlhepp will become Chief Executive Officer effective January 1, 2027. Mazumdar will move into the roles of Vice Chair of the Board and Strategic Advisor.
For investors, the quarterly loss is secondary to execution of the pivotal programme at this stage of Bicara’s development. The company’s ability to maintain enrollment momentum through year-end will be important for keeping the anticipated mid-2027 interim analysis on schedule, while its cash position provides runway beyond that potentially significant clinical catalyst.
Bicara Therapeutics stock price
